Clinical trials: Intravenous
Hypopituitarism
Acute Neuroendocrine Response to Intravenous Infusion of Diclofenac Sodium
The effects of acute administration of non-steroidal anti-inflammatory drugs (NSAIDs) on the neuroendocrine regulation of hydro-electrolytic metabolism are not precisely known to date.
- Trial name
- NCT05188131
- Testing
- Intravenous Infusion of Diclofenac Sodium
- Where
- Italy
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- A.O.U. Città della Salute e della Scienza
Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC)
QLS5132 Combination Therapy in Advanced Solid Tumors
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and effectiveness of the investigational drug QLS5132 (injectable) in combination with other therapies for participants with advanced…
- Conditions
- Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC), Endometrial Cancer, Advanced Solid Tumors
- Trial name
- NCT07453394
- Testing
- QLS5132; Bevacizumab, QLS5132; Platinum; Bevacizumab, QLS5132; Olaparib; Bevacizumab
- Volunteers
- 626 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Myocardial Injury
Impact of N-acetylcysteine Infusion and Intralipid Infusion on Myocardial Injury in Aluminum Phosphide Toxicity
Assess impact of ILE and NAC in morbidity and mortality when used as adjuvant therapy to routine management of acute ALP poisoning.
- Trial name
- NCT05370729
- Testing
- N-acetyl cysteine
- Volunteers
- 58 people
- Sponsor
- Assiut University
Unspecified Adult Solid Tumor, Protocol Specific
GSAO in Treating Patients With Advanced Solid Tumors That Have Not Responded to Therapy
RATIONALE: GSAO may stop the growth of solid tumors by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of GSAO in treating patients with advanced solid tumors that have not…
- Trial name
- NCT01147029
- Testing
- angiogenesis inhibitor GSAO, laboratory biomarker analysis, pharmacological study
- Where
- 2 sites in United Kingdom
- Volunteers
- 35 people
- Sponsor
- Cancer Research UK
Healthy
AZD Single Ascending Dose Study In Healthy Japanese Subjects
This is a single centre, open label, non-randomised study to access the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD3043 following a single dose administration to Japanese subjects.
- Trial name
- JSAD (NCT01028040)
- Testing
- AZD3043
- Where
- United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Small Cell Lung Cancer, Non-small Cell Lung Cancer
A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
This amended expansion phase of the protocol is to further the experience at a dose level of 150 mg CPT eq/m2 in patients with Stage IV non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) and to test for…
- Trial name
- NCT00455052
- Testing
- XMT-1001
- Where
- 12 sites in United States
- Volunteers
- 30 people
- Sponsor
- Mersana Therapeutics
Multiple Myeloma
Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple Myeloma
The purpose of this phase 3 study is to determine if subcutaneous velcade is non-inferior to intravenous velcade when administered in combination with low-dose dexamethasone in chinese refractory or relapsed multiple myeloma…
- Trial name
- NCT02811978
- Testing
- Bortezomib, Dexamethasone
- Where
- 10 sites in China
- Volunteers
- 81 people
- Sponsor
- Janssen Research & Development, LLC
Pain, Anxiety
Vibrating, Cold Device for Pediatric Intravenous (IV) Cannulation Pain Relief
The purpose of this study is to test the effectiveness of Buzzy®, a battery-powered reusable device that provides cold and vibration, in reducing the pain associated with intravenous (IV) cannulation.
- Trial name
- NCT01394250
- Testing
- Buzzy, Topical Lidocaine 4% Cream
- Where
- United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of Philadelphia
Surgery, Renal Cancer
Effects of Anesthesia on Immunity in Cancer
The aim of the study is a comparative study of the cellular immunity response of patients operated on for kidney cancer under total intravenous and inhalational anesthesia.
- Trial name
- NCT03514550
- Testing
- Propofol, Sevoflurane, Epidural block
- Where
- Russia
- Volunteers
- 20 people
- Sponsor
- Meshalkin Research Institute of Pathology of Circulation
Coagulation Disorder, Coagulation Function
Effects of Lipid Emulsions on Coagulation
The goal of this observational study is to learn how intravenous lipid emulsions may affect blood clotting function in hospitalized patients.
- Trial name
- NCT07470385
- Testing
- Lipid Emulsion
- Where
- China
- Volunteers
- 6,259 people
- Sponsor
- Mimi Tang, PhD
Vasoplegia Syndrome
Effects of Vitamin C on Shock Duration and Microcirculation in Patients With Vasoplegia Syndrome After Cardiac Surgery
This pilot study intends to observe the effect of intravenous vitamin C on the prognosis and sublingual microcirculation in patients with vasoplegia syndrome after cardiac surgery through a prospective randomized controlled study…
- Trial name
- NCT06723626
- Testing
- Vit C, Standard Preparation
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Southeast University, China
Healthy Volunteers
A Study to Evaluate the Effect of Single-Dose Intravenous Rifampin as a Prototypic Inhibitor of Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 on the Single-Dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants
The purpose of this study is to evaluate the effect of single dose intravenous rifampin on the single-dose PK of orally administered TAK-906.
- Trial name
- NCT04121078
- Testing
- TAK-906, Rifampin
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Millennium Pharmaceuticals, Inc.
Acute Myocardial Infarction
WJMSCs Anti-inflammatory Therapy in Acute Myocardial Infarction
Cumulative evidence has demonstrated that cardiac repair after acute myocardial infarction (AMI) is characterized by a series of time-dependent events orchestrated by the innate immune system.
- Trial name
- WAIAMI (NCT04551443)
- Testing
- Intravenous infusion WJMSCs
- Volunteers
- 200 people
- Sponsor
- Navy General Hospital, Beijing
Osteoarthritis, Arthritis
Efficacy And Safety Study Of Tanezumab Subcutaneous Administration In Osteoarthritis - A Subcutaneous/Intravenous Bridging Study
This is an efficacy and safety study of 3 doses (2.5 mg, 5 mg and 10mg) of tanezumab administered subcutaneously versus placebo.
- Conditions
- Osteoarthritis, Arthritis, Pain
- Trial name
- NCT01089725
- Testing
- Tanezumab SC, Tanezumab IV
- Where
- 91 sites in United States
- Volunteers
- 385 people
- Sponsor
- Pfizer
Alzheimer's Disease
A Study of SHR-1707 in Healthy Young Adult and Elderly Subjects
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single intravenous administration of SHR-1707 in healthy young adult and elderly subjects.
- Trial name
- NCT04973189
- Testing
- SHR-1707
- Where
- China
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Kidney Neoplasms
EPO906 Therapy in Patients With Advanced Kidney Cancer
This study will examine whether the investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause kidney cancer.
- Trial name
- NCT00035243
- Testing
- epothilone b
- Where
- 8 sites in United States, France
- Volunteers
- 53 people
- Sponsor
- Novartis Pharmaceuticals
Huntington Disease
Dose-response Evaluation of the Cellavita HD Product in Patients With Huntington's Disease
Cellavita HD is a stem-cell therapy for Huntington's Disease. This is a prospective, phase II, single-center, randomized (2:2:1), triple-blind, placebo controlled study, with two test doses of Cellavita HD product.
- Trial name
- ADORE-DH (NCT03252535)
- Testing
- Cellavita HD lower dose, Cellavita HD higher dose
- Where
- Brazil
- Volunteers
- 49 people
- Sponsor
- Azidus Brasil
Abuse, Drug
Abuse Potential of Intravenous Remimazolam Compared to Midazolam and Placebo in Recreational CNS Depressant Users
A double-blind, randomized crossover study to assess the subjective abuse potential of intravenous remimazolam compared to midazolam and placebo in recreational CNS depressant users
- Trial name
- NCT04110535
- Testing
- Remimazolam, Midazolam, Saline
- Where
- United States
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Paion UK Ltd.
Crohn Disease
A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease
The primary purpose of this study is to evaluate the efficacy and safety of a single intravenous (IV) re-induction dose of approximately 6 milligram per kilogram (mg/kg) ustekinumab in participants with secondary loss of response…
- Trial name
- POWER (NCT03782376)
- Testing
- Ustekinumab approximately 6 mg/kg (IV), Ustekinumab 90 mg (SC) Group 1, Ustekinumab 90 mg (SC) Group 2
- Where
- 104 sites in United States, Austria and 10 more
- Volunteers
- 215 people
- Sponsor
- Janssen-Cilag Ltd.
Myocardial Infarction, Angioplasty
Intracoronary Bolus Only Compared With Intravenous Bolus and 12-hours Infusion of Abciximab in Non-ST Elevation Myocardial Infarction.
Intracoronary bolus Abciximab single is non-inferior to intravenous and continuous 12- hours infusion in the size reduction of infarction on cardiac magnetic resonance in Non-ST elevation Myocardial infarction.
- Trial name
- NCT01080638
- Testing
- glycoprotein IIb/IIIa inhibitor (abciximab)
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Seoul National University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.